Immunology of age-related macular degeneration

Nature Reviews Immunology

Volumn 13, Issue 6, 2013, Pages 438-451

  Ambati, Jayakrishna ^a   Atkinson, John P ^b   Gelfand, Bradley D ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ARC 1905; BEVACIZUMAB; BROMFENAC; CHEMOKINE; CYTOKINE; DACLIZUMAB; ECULIZUMAB; FLUOCINOLONE ACETONIDE; GLATIRAMER; INFLAMMASOME; INFLIXIMAB; LAMPALIZUMAB; LFG 316; POT 4; RN 6G; SONEPCIZUMAB; TOLL LIKE RECEPTOR; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AGING; CELL TYPE; CLINICAL TRIAL; GENETICS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGY; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

AGED; AGING; BLINDNESS; COMPLEMENT FACTOR H; HUMANS; MACULAR DEGENERATION; MIDDLE AGED; MODELS, IMMUNOLOGICAL; MUTATION;

EID: 84878214672     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3459     Document Type: Review

References (160)

1. The Global Economic Cost of Visual Impairment. AMD Alliance International [online], http://www.icoph.org/resources/146/The-Global-Economic-Cost-of- Visual-Impairment.html (2010).
2. Haines, J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419-421 (2005).
3. Edwards, A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421-424 (2005).
4. Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005).
5. Hageman, G. S. et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA 102, 7227-7232 (2005).
6. Tuo, J., Grob, S., Zhang, K. & Chan, C. C. Genetics of immunological and inflammatory components in age-related macular degeneration. Ocul. Immunol. Inflamm. 20, 27-36 (2012).
7. Richards, A., Kavanagh, D. & Atkinson, J. P. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv. Immunol. 96, 141-177 (2007).
8. Khandhadia, S., Cipriani, V., Yates, J. R. & Lotery, A. J. Age-related macular degeneration and the complement system. Immunobiology 217, 127-146 (2012).
9. Anderson, D. H. et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 29, 95-112 (2010).
10. Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS ONE 3, e3554 (2008).
11. Bill, A., Sperber, G. & Ujiie, K. Physiology of the choroidal vascular bed. Int. Ophthalmol. 6, 101-107 (1983).
12. Hageman, G. S. et al. An integrated hypothesis that considers drusen as biomarkers of immunemediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20, 705-732 (2001).
13. Friedman, D. S. et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572 (2004).
14. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
15. Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006).
16. Bird, A. C. Therapeutic targets in age-related macular disease. J. Clin. Invest. 120, 3033-3041 (2010).
17. Sunness, J. S. et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 106, 1768-1779 (1999).
18. Martin, D. F. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119, 1388-1398 (2012).
19. Marneros, A. G. et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 167, 1451-1459 (2005).
20. Sepp, T. et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest. Ophthalmol. Visual Sci. 47, 536-540 (2006).
21. Sofat, R. et al. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int. J. Epidemiol. 41, 250-262 (2012).
22. Droz, I. et al. Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism. Br. J. Ophthalmol. 92, 513-517 (2008).
23. Magnusson, K. P. et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 3, e5 (2006).
24. Cameron, D. J. et al. HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration. Cell Cycle 6, 1122-1125 (2007).
25. Sobrin, L. et al. Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes. Ophthalmology 119, 1874-1875 (2012).
26. Young, R. W. Pathophysiology of age-related macular degeneration. Surv. Ophthalmol. 31, 291-306 (1987).
27. Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S. & Adamis, A. P. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 48, 257-293 (2003).
28. Sugita, S. Role of ocular pigment epithelial cells in immune privilege. Arch. Immunol. Ther. Exp. (Warsz.) 57, 263-268 (2009).
29. Streilein, J. W. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond.) 9, 236-240 (1995).
30. Morohoshi, K., Goodwin, A. M., Ohbayashi, M. & Ono, S. J. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J. Autoimmun. 33, 247-254 (2009).
31. Xu, H., Chen, M., Manivannan, A., Lois, N. & Forrester, J. V. Age-dependent accumulation of lipofuscin in perivascular and subretinal microglia in experimental mice. Aging Cell 7, 58-68 (2008).
32. Ma, W., Zhao, L., Fontainhas, A. M., Fariss, R. N. & Wong, W. T. Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD. PLoS ONE 4, e7945 (2009).
33. Chen, M., Forrester, J. V. & Xu, H. Dysregulation in retinal para-inflammation and age-related retinal degeneration in CCL2 or CCR2 deficient mice. PLoS ONE 6, e22818 (2011).
34. Tuo, J. et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 48, 3827-3836 (2007).
35. Xu, H., Chen, M. & Forrester, J. V. Para-inflammation in the aging retina. Prog. Retin. Eye Res. 28, 348-368 (2009).
36. Sakurai, E., Anand, A., Ambati, B. K., van Rooijen, N. & Ambati, J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 3578-3585 (2003).
37. Espinosa-Heidmann, D. G. et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 3586-3592 (2003).
38. Shen, W. Y., Yu, M. J., Barry, C. J., Constable, I. J. & Rakoczy, P. E. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br. J. Ophthalmol. 82, 1063-1071 (1998).
39. Ambati, J. et al. An animal model of age-related macular degeneration in senescent Ccl-2-or Ccr-2-deficient mice. Nature Med. 9, 1390-1397 (2003).
40. Combadiere, C. et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 117, 2920-2928 (2007).
41. Ross, R. J. et al. Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. Exp. Res. 86, 675-683 (2008).
42. Luhmann, U. F. et al. The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages. Invest. Ophthalmol. Vis. Sci. 50, 5934-5943 (2009).
43. Bruban, J. et al. CCR2/CCL2-mediated inflammation protects photoreceptor cells from amyloid-β-induced apoptosis. Neurobiol. Dis. 42, 55-72 (2011).
44. Raoul, W. et al. Lipid-bloated subretinal microglial cells are at the origin of drusen appearance in CX3CR1-deficient mice. Ophthalmic Res. 40, 115-119 (2008).
45. Tuo, J. et al. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 18, 1297-1299 (2004).
46. Chen, H., Liu, B., Lukas, T. J. & Neufeld, A. H. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS ONE 3, e2339 (2008).
47. Seidler, S., Zimmermann, H. W., Bartneck, M., Trautwein, C. & Tacke, F. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol. 11, 30 (2010).
48. Liu, J. et al. Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization. J. Biol. Chem. 286, 20991-21001 (2011).
49. Xie, P. et al. Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. PLoS ONE 6, e28933 (2011).
50. Raychaudhuri, S. et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nature Genet. 43, 1232-1236 (2011).
51. Anderson, D. H., Mullins, R. F., Hageman, G. S. & Johnson, L. V. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134, 411-431 (2002).
52. Baudouin, C. et al. Immunohistological study of subretinal membranes in age-related macular degeneration. Jpn. J. Ophthalmol. 36, 443-451 (1992).
53. Clark, S. J. et al. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J. Biol. Chem. 285, 30192-30202 (2010).
54. Sjöberg, A. P. et al. The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J. Biol. Chem. 282, 10894-10900 (2007).
55. Laine, M. et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J. Immunol. 178, 3831-3836 (2007).
56. Johnson, P. T. et al. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc. Natl Acad. Sci. USA 103, 17456-17461 (2006).
57. Hollyfield, J. G. et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nature Med. 14, 194-198 (2008).
58. Doyle, S. L. et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nature Med. 18, 791-798 (2012).
59. Tarallo, V. et al. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149, 847-859 (2012).
60. Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325-330 (2011).
61. Tseng, W. A. et al. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 54, 110-120 (2013).
62. Kauppinen, A. et al. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-Implications for age-related macular degeneration (AMD). Immunol. Lett. 147, 29-33 (2012).
63. Liu, R. T. et al. Inflammatory mediators induced by amyloid-β in the retina and RPE in vivo: implications for inflammasome activation in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 54, 2225-2237 (2013).
64. Kleinman, M. E. et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
65. Kleinman, M. E. et al. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol. Ther. 20, 101-108 (2012).
66. Lavalette, S. et al. Interleukin-1β inhibition prevents choroidal neovascularization and does not exacerbate photoreceptor degeneration. Am. J. Pathol. 178, 2416-2423 (2011).
67. Kumar, M. V., Nagineni, C. N., Chin, M. S., Hooks, J. J. & Detrick, B. Innate immunity in the retina: toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J. Neuroimmunol. 153, 7-15 (2004).
68. Yang, Z. et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N. Engl. J. Med. 359, 1456-1463 (2008).
69. Zareparsi, S. et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. Hum. Mol. Genet. 14, 1449-1455 (2005).
70. Cho, Y. et al. Toll-like receptor polymorphisms and age-related macular degeneration: replication in three case-control samples. Invest. Ophthalmol. Vis. Sci. 50, 5614-5618 (2009).
71. Shiose, S. et al. Toll-like receptor 3 is required for development of retinopathy caused by impaired alltrans-retinal clearance in mice. J. Biol. Chem. 286, 15543-15555 (2011).
72. West, X. Z. et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467, 972-976 (2010).
73. Fujimoto, T. et al. Choroidal neovascularization enhanced by Chlamydia pneumoniae via Toll-like receptor 2 in the retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 51, 4694-4702 (2010).
74. Patel, N. et al. Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology 115, 422-430 (2005).
75. Penfold, P. L., Provis, J. M., Furby, J. H., Gatenby, P. A. & Billson, F. A. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 228, 270-274 (1990).
76. Cherepanoff, S., Mitchell, P., Wang, J. J. & Gillies, M. C. Retinal autoantibody profile in early age-related macular degeneration: preliminary findings from the Blue Mountains Eye Study. Clin. Exp. Ophthalmol. 34, 590-595 (2006).
77. Zhou, J., Jang, Y. P., Kim, S. R. & Sparrow, J. R. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc. Natl Acad. Sci. USA 103, 16182-16187 (2006).
78. Fernandes, A. F. et al. Oxidative inactivation of the proteasome in retinal pigment epithelial cells. A potential link between oxidative stress and up-regulation of interleukin-8. J. Biol. Chem. 283, 20745-20753 (2008).
79. Bian, Q. et al. Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells. Free Radic. Biol. Med. 53, 1298-1307 (2012).
80. Sparrow, J. R., Zhou, J. & Cai, B. DNA is a target of the photodynamic effects elicited in A2E-laden RPE by blue-light illumination. Invest. Ophthalmol. Vis. Sci. 44, 2245-2251 (2003).
81. Sparrow, J. R., Nakanishi, K. & Parish, C. A. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest. Ophthalmol. Vis. Sci. 41, 1981-1989 (2000).
82. Radu, R. A. et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J. Biol. Chem. 286, 18593-18601 (2011).
83. Iriyama, A. et al. A2E, a component of lipofuscin, is pro-angiogenic in vivo. J. Cell. Physiol. 220, 469-475 (2009).
84. Catala, A. Lipid peroxidation of membrane phospholipids in the vertebrate retina. Front. Biosci. (Schol Ed) 3, 52-60 (2011).
85. Hoppe, G., O'Neil, J., Hoff, H. F. & Sears, J. Products of lipid peroxidation induce missorting of the principal lysosomal protease in retinal pigment epithelium. Biochim. Biophys. Acta 1689, 33-41 (2004).
86. Krohne, T. U., Stratmann, N. K., Kopitz, J. & Holz, F. G. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp. Res. 90, 465-471 (2010).
87. Weismann, D. et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478, 76-81 (2011).
88. Sharma, A. et al. 4-Hydroxynonenal induces p53-mediated apoptosis in retinal pigment epithelial cells. Arch. Biochem. Biophys. 480, 85-94 (2008).
89. Dentchev, T., Milam, A. H., Lee, V. M., Trojanowski, J. Q. & Dunaief, J. L. Amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol. Vision 9, 184-190 (2003).
90. Ding, J. D. et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc. Natl Acad. Sci. USA 108, e279-e287 (2011).
91. Liu, X. C., Liu, X. F., Jian, C. X., Li, C. J. & He, S. Z. IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells. Inflammation 35, 776-784 (2012).
92. Ambati, J. & Fowler, B. J. Mechanisms of age-related macular degeneration. Neuron 75, 26-39 (2012).
93. Killingsworth, M. C., Sarks, J. P. & Sarks, S. H. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye (Lond.) 4, 613-621 (1990).
94. Lopez, P. F. et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am. J. Ophthalmol. 112, 647-656 (1991).
95. Oh, H. et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 40, 1891-1898 (1999).
96. Seregard, S., Algvere, P. V. & Berglin, L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch. Clin. Exp. Ophthalmol. 232, 325-329 (1994).
97. Tsutsumi-Miyahara, C. et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br. J. Ophthalmol. 88, 1217-1222 (2004).
98. Cherepanoff, S., McMenamin, P., Gillies, M. C., Kettle, E. & Sarks, S. H. Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br. J. Ophthalmol. 94, 918-925 (2010).
99. Grossniklaus, H. E. et al. Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch. Ophthalmol. 118, 625-629 (2000).
100. Apte, R. S., Richter, J., Herndon, J. & Ferguson, T. A. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 3, e310 (2006).
101. Cao, X. et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol. Int. 61, 528-535 (2011).
102. Hasegawa, E. et al. IL-27 inhibits pathophysiological intraocular neovascularization due to laser burn. J. Leukoc. Biol. 91, 267-273 (2012).
103. Matsumura, N. et al. Low-dose lipopolysaccharide pretreatment suppresses choroidal neovascularization via IL-10 induction. PLoS ONE 7, e39890 (2012).
104. Kelly, J., Ali Khan, A., Yin, J., Ferguson, T. A. & Apte, R. S. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J. Clin. Invest. 117, 3421-3426 (2007).
105. Zhou, J. et al. Neutrophils promote experimental choroidal neovascularization. Mol. Vision 11, 414-424 (2005).
106. Zhou, J. et al. Neutrophils compromise retinal pigment epithelial barrier integrity. J. Biomed. Biotechnol. 2010, 289360 (2010).
107. Penfold, P. L., Provis, J. M. & Billson, F. A. Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch. Clin. Exp. Ophthalmol. 225, 70-76 (1987).
108. Luo, L. et al. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 7, 3264-3275 (2013)
109. Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897-1908 (2011).
110. Jonas, J. B., Degenring, R. F., Kreissig, I., Friedemann, T. & Akkoyun, I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye (Lond.) 19, 163-170 (2005).
111. Gillies, M. C. et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol. 121, 667-673 (2003).
112. Smailhodzic, D. et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 119, 2304-2311 (2012).
113. Hagstrom, S. A. et al. Pharmacogenetics for genes associated with age-related macular degeneration (AMD) in the comparison of AMD treatments trials (CATT). Ophthalmology 120, 593-599 (2013).
114. Scholl, H. P. et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE 4, e7418 (2009).
115. Klein, M. L. et al. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 117, 1554-1559.e1 (2010).
116. Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl Acad. Sci. USA 103, 2328-2333 (2006).
117. Curcio, C. A. et al. Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, prevalence, yopography, and biogenesis model. Retina 33, 265-276 (2013).
118. Johnson, L. V. et al. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc. Natl Acad. Sci. USA 108, 18277-18282 (2011).
119. Wang, A. L. et al. Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration. PLoS ONE 4, e4160 (2009).
120. Munch, I. C. et al. Small, hard macular drusen and peripheral drusen: associations with AMD genotypes in the Inter99 Eye Study. Invest. Ophthalmol. Vis. Sci. 51, 2317-2321 (2010).
121. Seddon, J. M., Reynolds, R. & Rosner, B. Peripheral retinal drusen and reticular pigment: association with CFHY402H and CFHrs1410996 genotypes in family and twin studies. Invest. Ophthalmol. Vis. Sci. 50, 586-591 (2009).
122. Hageman, G. S. & Mullins, R. F. Molecular composition of drusen as related to substructural phenotype. Mol. Vis. 5, 28 (1999).
123. Crabb, J. W. et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 14682-14687 (2002).
124. Hollyfield, J. G., Salomon, R. G. & Crabb, J. W. Proteomic approaches to understanding age-related macular degeneration. Adv. Exp. Med. Biol. 533, 83-89 (2003).
125. Johnson, L. V. et al. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 11830-11835 (2002).
126. Klein, M. L. et al. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 115, 1026-1031 (2008).
127. Friese, M. A. et al. FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol. Immunol. 36, 809-818 (1999).
128. Spencer, K. L. et al. Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. Hum. Mol. Genet. 17, 971-977 (2008).
129. Heurich, M. et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc. Natl Acad. Sci. USA 108, 8761-8766 (2011).
130. Takeda, A. et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy Nature 460, 225-230 (2009).
131. Wang, H. et al. Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and-independent signaling. Invest. Ophthalmol. Vis. Sci. 52, 8271-8277 (2011).
132. Mo, F M., Proia, A. D., Johnson, W. H., Cyr, D. & Lashkari, K. Interferon y-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 51, 4226-4236 (2010).
133. Sharma, N. K. et al. New biomarker for neovascular age-related macular degeneration: eotaxin-2. DNA Cell Biol. 31, 1618-1627 (2012).
134. Mizutani, T., Ashikari, M., Tokoro, M., Nozaki, M. & Ogura, Y. Suppression of laser-induced choroidal neovascularization by a CCR3 antagonist. Invest. Ophthalmol. Vis. Sci. 54, 1564-1572 (2013).
135. Seddon, J. M., George, S., Rosner, B. & Rifai, N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch. Ophthalmol. 123, 774-782 (2005).
136. Dankbar, B. et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95, 2630-2636 (2000).
137. Izumi-Nagai, K. et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am. J. Pathol. 170, 2149-2158 (2007).
138. Leung, K. W., Barnstable, C. J. & Tombran-Tink, J. Bacterial endotoxin activates retinal pigment epithelial cells and induces their degeneration through IL-6 and IL-8 autocrine signaling. Mol. Immunol. 46, 1374-1386 (2009).
139. Fujimura, S. et al. Angiostatic effect of CXCR3 expressed on choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 53, 1999-2006 (2012).
140. Arakawa, S. et al. Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population. Nature Genet. 43, 1001-1004 (2011).
141. Nakata, I. et al. Association of genetic variants on 8p21 and 4q12 with age-related macular degeneration in Asian populations. Invest. Ophthalmol. Vis. Sci. 53, 6576-6581 (2012).
142. Lichtlen, P., Lam, T. T., Nork, T. M., Streit, T. & Urech, D. M. Relative contribution of VEGF and TNF-a in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest. Ophthalmol. Vis. Sci. 51, 4738-4745 (2010).
143. Olson, J. L., Courtney, R. J. & Mandava, N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch. Ophthalmol. 125, 1221-1224 (2007).
144. Shi, X. et al. Inhibition of TNF-a reduces laser-induced choroidal neovascularization. Exp. Res. 83, 1325-1334 (2006).
145. de Oliveira Dias, J. R. et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br. J. Ophthalmol. 95, 1631-1637 (2011).
146. Sengupta, N. et al. Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. Invest. Ophthalmol. Vis. Sci. 46, 343-348 (2005).
147. Lee, E. & Rewolinski, D. Evaluation of CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 51, 3666-3672 (2010).
148. Guerin, E. et al. SDF1-ais associated with VEGFR-2 in human choroidal neovascularisation. Microvasc. Res. 75, 302-307 (2008).
149. Bhutto, I. A., McLeod, D. S., Merges, C, Hasegawa, T & Lutty, G. A. Localisation of SDF-1 and its receptor CXCR4 in retina and choroid of aged human eyes and in eyes with age related macular degeneration. Br. J. Ophthalmol. 90, 906-910 (2006).
150. Mevorach, D. Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system. Apoptosis 15, 1114-1123 (2010).
151. Wang, Q. et al. Identification of a central role for complement in osteoarthritis. Nature Med. 17, 1674-1679 (2011).
152. Wu, G. et al. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 104, 550-558 (2009).
153. Szeplaki, G., Varga, L, Fust, G. & Prohaszka, Z. Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol. Immunol. 46, 2784-2793 (2009).
154. Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nature Immunol. 12, 204-212 (2011).
155. Fritsche, L. G. et al. Seven new loci associated with age-related macular degeneration. Nature Genet. 45, 433-439 (2013).
156. Landa, G., Butovsky, O., Shoshani, J., Schwartz, M. & Pollack, A. Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr. Res. 33, 1011-1013 (2008).
157. Nussenblatt, R. B. et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 30, 1579-1587 (2010).
158. Gomi, F, Sawa, M., Tsujikawa, M. & Nishida, K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 32, 1804-1810 (2012).
159. Ahmadieh, H. et al. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial. Retina 31, 1819-1826 (2011).
160. Lachmann, P. J. The amplification loop of the complement pathways. Adv. Immunol. 104, 115-149 (2009).